WO2006029838A3 - Secreted polypeptide species involved in alzheimer’s disease - Google Patents

Secreted polypeptide species involved in alzheimer’s disease Download PDF

Info

Publication number
WO2006029838A3
WO2006029838A3 PCT/EP2005/009875 EP2005009875W WO2006029838A3 WO 2006029838 A3 WO2006029838 A3 WO 2006029838A3 EP 2005009875 W EP2005009875 W EP 2005009875W WO 2006029838 A3 WO2006029838 A3 WO 2006029838A3
Authority
WO
WIPO (PCT)
Prior art keywords
alzheimer
disease
secreted polypeptide
species involved
polypeptide species
Prior art date
Application number
PCT/EP2005/009875
Other languages
French (fr)
Other versions
WO2006029838A2 (en
Inventor
Thierry Baussant
Lydie Bougueleret
Isabelle Cusin
Eve Mahe
Anne Niknejad
Samia Reffas
Original Assignee
Geneprot Inc
Thierry Baussant
Lydie Bougueleret
Isabelle Cusin
Eve Mahe
Anne Niknejad
Samia Reffas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geneprot Inc, Thierry Baussant, Lydie Bougueleret, Isabelle Cusin, Eve Mahe, Anne Niknejad, Samia Reffas filed Critical Geneprot Inc
Publication of WO2006029838A2 publication Critical patent/WO2006029838A2/en
Publication of WO2006029838A3 publication Critical patent/WO2006029838A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

The invention discloses human secreted polypeptides whose concentrations are specifically altered in the CSF obtained from individuals with Alzheimer's disease, when compared to the same from individuals free from Alzheimer's disease. The invention also provides methods of using compositions including the polypeptides, polynucleotides encoding them, and antibodies specific for these polypeptides, for diagnosis and prognosis of Alzheimer's disease, and for drug development.
PCT/EP2005/009875 2004-09-14 2005-09-14 Secreted polypeptide species involved in alzheimer’s disease WO2006029838A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61008204P 2004-09-14 2004-09-14
US60/610,082 2004-09-14

Publications (2)

Publication Number Publication Date
WO2006029838A2 WO2006029838A2 (en) 2006-03-23
WO2006029838A3 true WO2006029838A3 (en) 2006-07-06

Family

ID=35285248

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/009875 WO2006029838A2 (en) 2004-09-14 2005-09-14 Secreted polypeptide species involved in alzheimer’s disease

Country Status (1)

Country Link
WO (1) WO2006029838A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014014353A1 (en) 2012-07-18 2014-01-23 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno New classification method for spectral data
EP3567371A1 (en) * 2013-03-15 2019-11-13 Sera Prognostics, Inc. Biomarkers and methods for predicting preeclampsia
PL3311158T3 (en) 2015-06-19 2023-11-27 Sera Prognostics, Inc. Biomarker pairs for predicting preterm birth
WO2019036032A1 (en) 2017-08-18 2019-02-21 Sera Prognostics, Inc Pregnancy clock proteins for predicting due date and time to birth

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001075454A2 (en) * 2000-04-03 2001-10-11 Oxford Glycosciences (Uk) Ltd. Diagnosis and treatment of alzheimer's disease
EP1408333A2 (en) * 2001-10-03 2004-04-14 Pfizer Products Inc. Diagnosis and treatment of Alzheimer's disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001075454A2 (en) * 2000-04-03 2001-10-11 Oxford Glycosciences (Uk) Ltd. Diagnosis and treatment of alzheimer's disease
EP1408333A2 (en) * 2001-10-03 2004-04-14 Pfizer Products Inc. Diagnosis and treatment of Alzheimer's disease

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
EDER U ET AL: "Levels and proteolytic processing of chromogranin A and B and secretogranin II in cerebrospinal fluid in neurological diseases", JOURNAL OF NEURAL TRANSMISSION, SPRINGER VERLAG, VIENNA, AT, vol. 105, no. 1, 1998, pages 39 - 51, XP002256794, ISSN: 0300-9564 *

Also Published As

Publication number Publication date
WO2006029838A2 (en) 2006-03-23

Similar Documents

Publication Publication Date Title
WO2005011599A3 (en) Antibodies specific for toxic amyloid beta protein oligomers
WO2002046222A3 (en) Compositions and methods for diagnosing alzheimer's disease
WO2005047484A3 (en) Biomarkers for alzheimer's disease
WO2004009622A3 (en) Protein complexes of cellular networks underlying the development of cancer and other diseases
WO2006035237A3 (en) Methods and compositions relating to alzheimer's disease
MX2007013626A (en) Antibodies directed against amyloid-beta peptide and methods using same.
WO2007067730A3 (en) Human monoclonal antibodies to protein tyrosine kinase 7 ( ptk7 ) and their use
EP2322551A3 (en) Compositions comprising Anti-IGF-1R Antibodies and Methods for their Production
WO2005098433A3 (en) Diagnostic assays for alzheimer’s disease
WO2003066661A3 (en) Human dr4 antibodies and uses thereof
WO2005018424A3 (en) Antibodies specific for fibrillar amyloid and a procedure to detect fibrillar amyloid deposits
WO2006005583A3 (en) Secreted polypeptide species involved in multiple sclerosis
WO2006125201A3 (en) Anti-biotin-pegylated-mcp-1 mutein antibodies, compositions, methods and uses
WO2002088750A3 (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
WO2003028543A3 (en) Nucleic acid molecules, polypeptides and uses therefor, including diagnosis and treatment of alzheimer's disease
ZA200702318B (en) Nanobodies against amyloid-beta and polypeptides comprising the same for the treatment of degenerative neual diseases such as alzheimer's disease
WO2006029838A3 (en) Secreted polypeptide species involved in alzheimer’s disease
MXPA02008239A (en) Human schizophrenia gene.
WO2005014635A3 (en) Secreted polypeptide species reduced in cardiovascular disorders
WO2006069765A3 (en) Secreted polypeptide species involved in multiple sclerosis
WO2005015206A3 (en) Secreted polypeptide species associated with cardiovascular disorders
WO2002073212A3 (en) Diagnostic screens for alzheimer's disease
WO2002079398A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2004106941A3 (en) Secreted polypeptide species associated with cardiovascular disorders
WO2002099116A8 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 69(1) EPC (EPO FORM 1205A DATED 05.07.2007)

122 Ep: pct application non-entry in european phase

Ref document number: 05787425

Country of ref document: EP

Kind code of ref document: A2

WWW Wipo information: withdrawn in national office

Ref document number: 5787425

Country of ref document: EP